publication date: Nov. 8, 2019
Sharpless returns to NCI; Hahn to be nominated FDA commissioner; Giroir assumes acting role
By Alex Carolan
Norman E. Sharpless has returned to his previous role of NCI director earlier this week after serving as acting FDA commissioner since April 5.
On Nov. 1, President Donald Trump announced his intent to nominate Stephen M. Hahn, chief medical executive at MD Anderson Cancer Center and a professor in the Department of Radiation Oncology, to the top job at FDA.
Confirmation in the Senate is expected to take several months. In the interim, HHS Assistant Secretary of Health Brett Giroir is stepping in as acting FDA commissioner.
Sharpless’ time as acting commissioner expired Nov. 1, under the Federal Vacancies Reform Act (The Cancer Letter, Nov. 1).
With Sharpless’s return, Douglas R. Lowy returns to his past role as principal deputy director. Lowy served as acting NCI director from April through Nov. 1.
On Nov. 6, Sharpless announced his homecoming in an email to NCI staff, subject-lined “Happy to be back!”
“My time at FDA was inspiring and educational, and deepened my appreciation of the complex interplay between FDA and NIH,” Sharpless wrote. “But as I have said before, I believe the role of NCI Director is the best job in government.
“I am well aware that what makes NCI great is each of you and your commitment to our mission,” Sharpless wrote. “I anticipate my return will be as seamless as my arrival and I thank you in advance for your continued focus on the work at hand. It is my great privilege to work with you again.”
Sharpless is a … Continue reading Sharpless returns to NCI; Hahn to be nominated FDA commissioner; Giroir assumes acting role
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP
If you're not a subscriber why not join today?
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.